Stock Events

Stock Events

Madrigal Pharmaceuticals 

€473.10
73
+€10.20+2.2% Wednesday 10:40

Statistics

Day High
473.1
Day Low
473.1
52W High
475.3
52W Low
400
Volume
15
Avg. Volume
-
Mkt Cap
10.91B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q1 2026
Next
-3.6
-3.2
-2.8
-2.41
Expected EPS
-2.4057408550500003
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YDO1.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap4.35B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, directly competing with Madrigal's NASH treatments.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences has a strong focus on liver diseases, including NASH, positioning it as a competitor in the same therapeutic area as Madrigal.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.38M
Galmed Pharmaceuticals is developing treatments for liver diseases, including NASH, making it a direct competitor to Madrigal.
Agios Pharmaceuticals
AGIO
Mkt Cap2.22B
Agios Pharmaceuticals focuses on metabolic disorders, competing in the same space as Madrigal's treatments for liver diseases.
Axsome Therapeutics
AXSM
Mkt Cap12.57B
Axsome Therapeutics, while primarily focused on CNS disorders, has interests in metabolic disorders, potentially putting it in competition with Madrigal.
Novartis
NVS
Mkt Cap305.1B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for liver diseases, making it a potential competitor to Madrigal in the NASH space.

About

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Show more...
CEO
ISIN
US5588681057
WKN
000A2APCZ

Listings

MI
IT
1MDGL.MI
XETRA
DE
YDO1.XETRA
STU
DE
YDO1.STU
LSE
GB
0JXI.LSE

0 Comments

Share your thoughts

FAQ

What is Madrigal Pharmaceuticals stock price today?▼
The current price of YDO1.XETRA is €473.10 EUR — it has increased by +2.2% in the past 24 hours. Watch Madrigal Pharmaceuticals stock price performance more closely on the chart.
What is Madrigal Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Madrigal Pharmaceuticals stocks are traded under the ticker YDO1.XETRA.
What is Madrigal Pharmaceuticals market cap?▼
Today Madrigal Pharmaceuticals has the market capitalization of 10.91B
When is the next Madrigal Pharmaceuticals earnings date?▼
Madrigal Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Madrigal Pharmaceuticals earnings last quarter?▼
YDO1.XETRA earnings for the last quarter are -2.77 EUR per share, whereas the estimation was -3.6 EUR resulting in a +23.16% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Madrigal Pharmaceuticals located?▼
Madrigal Pharmaceuticals operates in the Other sector.
When did Madrigal Pharmaceuticals complete a stock split?▼
The last stock split for Madrigal Pharmaceuticals was on July 25, 2016 with a ratio of 1:35.